Patents by Inventor Jeffrey R. Marks

Jeffrey R. Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene Expression Signatures for Oncogenic Pathway Deregulation
    Publication number: 20090186024
    Abstract: The disclosure relates to identifying deregulated pathways in cancer. In certain embodiments, the methods of the disclosure can be used to evaluate therapeutic agents for the treatment of cancer.
    Type: Application
    Filed: May 15, 2006
    Publication date: July 23, 2009
    Inventors: Joseph R. Nevins, Andrea H. Bild, Guang Yao, Jeffrey T. Chang, Quanli Wang, Anil Potti, David Harpole, Johnathan M. Lancaster, Andrew Berchuck, John A. Olson, Jeffrey R. Marks, Mike West, Holly Dressman
  • Methods for evaluating the ability to metabolize pharmaceuticals
    Patent number: 6929912
    Abstract: Methods for detecting variant genes having a polymorphism associated with reduced metabolism of a substrate selected from the group consisting of a CYP3A4 substrate, a CYP3A5 substrate and a GSTM1 substrate in an individual are disclosed. The methods are genotyping methods to identify specific polymorphisms which have been found to be associated with reduced metabolism of chemotherapeutic agents, such as cyclophosphamide and BCNU. Also disclosed are novel polymorphic nucleic acid molecules useful in the methods of the invention.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: August 16, 2005
    Assignees: Genaissance Pharmaceuticals, Inc., Duke University
    Inventors: Marco Guida, Jeff Hall, William P. Petros, James J. Vredenburgh, Oliver M. Colvin, Jeffrey R. Marks
  • Methods for evaluating the ability to metabolize pharmaceuticals and compositions therefor
    Publication number: 20030096251
    Abstract: Methods for detecting variant genes having a polymorphism associated with reduced metabolism of a substrate selected from the group consisting of a CYP3A4 substrate, a CYP3A5 substrate and a GSTM1 substrate in an individual are disclosed. The methods are genotyping methods to identify specific polymorphisms which have been found to be associated with reduced metabolism of chemotherapeutic agents, such as cyclophosphamide and BCNU. Also disclosed are novel polymorphic nucleic acid molecules useful in the methods of the invention.
    Type: Application
    Filed: February 26, 2002
    Publication date: May 22, 2003
    Inventors: Marco Guida, Jeff Hall, William P. Petros, James J. Vredenburgh, Oliver M. Colvin, Jeffrey R. Marks
  • Antisense oligonucleotides against ERBB-2
    Patent number: 5910583
    Abstract: Oligonucleotides consisting of the nucleotide sequence US-3 ?GGT GCT CAC TGC GGC (SEQ ID NO:2)! or UT-1 ?TGC GGC TCC GGC CCC (SEQ ID NO:5)!. The oligonucleotides are useful as antisense oligonucleotides for inhibiting the expression of the ERBB2 tyrosine kinase receptor in a cell, in vitro or in vivo.
    Type: Grant
    Filed: November 4, 1996
    Date of Patent: June 8, 1999
    Assignee: Duke University
    Inventors: Jeffrey R. Marks, James P. Vaughn, James D. Inglehart